SVRA (Savara) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 25, 2026)


SVRA Savara Inc SVRA
19 GF Score
Price $5.96
! 3 Warning Signs
View Full Analysis

What is Savara Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Savara's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

SVRA vs ABSI, CRVS, JBIO: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, Savara's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Savara Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Savara's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Savara's Margin of Safety % (DCF FCF Based) falls into.


SVRA
19GF Score
Savara Inc SVRA
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Savara Business Description

Other Exchanges YB4P:Germany
Address 1717 Langhorne Newtown Road, Suite 300, One Summit Square, Langhorne, PA, USA, 19047
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
19GF Score

Get the complete analysis for SVRA

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.96
Price